Healthcare / BiotechnologyStockholm
$2.13
-0.03 (-1.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-162.8M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$530M
P/E
3.3x
↓EV/EBITDA
1.7x
↓ROE
55.3%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
47.3%
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $316.7M · net income $147.0M · FCF $149.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $316.7M | $316.7M | — | — | — |
| Net Income | $147.0M | $147.0M | $-161.7M | $-280.0M | $-371.8M |
| EBITDA | $154.4M | $154.4M | $-158.2M | $-276.6M | $-368.1M |
| EPS | 0.58 | 0.58 | -0.88 | -1.65 | -2.90 |
| Operating Margin | 48.7% | 48.7% | — | — | — |
| Net Margin | 46.4% | 46.4% | — | — | — |
| Balance Sheet | |||||
| Current Ratio | 8.09 | 8.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $149.7M | $149.7M | $-162.8M | $-286.7M | $-366.0M |
| Returns | |||||
| ROE | 55.3% | 55.3% | -139.0% | -165.9% | -95.4% |
| Valuation | |||||
| P/E | 3.33 | 3.33 | — | — | — |
| EV/EBITDA | 1.68 | 1.68 | — | — | — |
| P/B | 2.04 | 2.04 | 2.66 | 3.74 | 1.63 |
| Growth & Yield | |||||
| EPS Growth | 165.9% | 165.9% | 46.7% | 43.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-31.2%
EPS terminal req.
$0.19
Spread vs growth
197.1%
5Y implied EPS CAGR
-17.0%
EPS terminal req.
$0.23
Spread vs growth
182.9%
10Y implied EPS CAGR
-4.4%
EPS terminal req.
$0.37
Spread vs growth
170.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+44.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.88 → 0.58
Residual
+44.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.